Exelixis Inc. | Large-cap | Healthcare
$46.15
4.18%
| Exelixis Stock Comparison:
Exelixis vs VertexExelixis vs RegeneronExelixis vs AlnylamExelixis vs Royalty Pharma plcExelixis vs InsmedExelixis vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.2B
Gross Profit 2.1B 96.49%
Operating Income 689.9M 31.81%
Net Income 521.3M 24.04%
EPS (Diluted) $1.76

Balance Sheet Metrics

Total Assets 2.9B
Total Liabilities 703.5M
Shareholders Equity 2.2B
Debt to Equity 0.31

Cash Flow Metrics

Operating Cash Flow 604.6M
Free Cash Flow 633.8M

Revenue & Profitability Trend

Exelixis Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue2.2B1.8B1.6B1.4B987.5M
Cost of Goods Sold76.2M72.5M57.9M52.9M36.3M
Gross Profit2.1B1.8B1.6B1.4B951.3M
Operating Expenses1.4B1.6B1.4B1.1B841.2M
Operating Income689.9M170.9M201.5M286.7M110.1M
Pre-tax Income681.6M257.5M234.4M294.2M130.8M
Income Tax160.4M49.8M52.1M63.1M19.1M
Net Income521.3M207.8M182.3M231.1M111.8M
EPS (Diluted)$1.76$0.65$0.56$0.72$0.35

Income Statement Trend

Exelixis Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.5B1.3B1.6B1.8B1.4B
Non-Current Assets1.5B1.6B1.5B781.5M691.9M
Total Assets2.9B2.9B3.1B2.6B2.1B
Liabilities
Current Liabilities403.8M394.3M324.4M337.6M204.7M
Non-Current Liabilities299.7M284.2M258.7M68.0M53.6M
Total Liabilities703.5M678.4M583.1M405.6M258.2M
Equity
Total Shareholders Equity2.2B2.3B2.5B2.2B1.9B

Balance Sheet Composition

Exelixis Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income521.3M207.8M182.3M231.1M111.8M
Operating Cash Flow604.6M361.8M453.9M370.4M234.2M
Investing Activities
Capital Expenditures-28.4M-40.5M-27.7M-54.2M-30.3M
Investing Cash Flow-79.0M95.5M-413.7M-32.9M-131.2M
Financing Activities
Dividends Paid-----
Financing Cash Flow-690.7M-579.5M-23.3M-39.1M-50.0M
Free Cash Flow633.8M170.4M224.2M336.6M178.6M

Cash Flow Trend

Exelixis Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 19.80
Forward P/E 25.51
Price to Book 5.60
Price to Sales 5.14
PEG Ratio 25.51

Profitability Ratios

Profit Margin 27.99%
Operating Margin 33.64%
Return on Equity 30.22%
Return on Assets 18.05%

Financial Health

Current Ratio 3.50
Debt to Equity 8.78
Beta 0.28

Per Share Data

EPS (TTM) $2.19
Book Value per Share $7.75
Revenue per Share $8.08

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
exel11.8B19.805.6030.22%27.99%8.78
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Alnylam 40.8B-353.42-414.62%-11.49%2,358.26
Royalty Pharma plc 20.3B14.752.3018.00%48.26%77.82
Insmed 20.0B-193.43-320.20%-265.93%1,316.96

Financial data is updated regularly. All figures are in the company's reporting currency.